Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

The California Plasma Coalition (CalPlasma) today launched a statewide campaign to raise awareness of the vital role that plasma donations play in saving lives of Californians and patients around the ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...

Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) has earned an average recommendation of “Buy” from the seven ratings firms that are presently covering the company, Marketbeat Ratings ...

Nature Research Intelligence Topics enable transformational understanding and discovery in research by categorising any document into meaningful, accessible topics. Read this blog to understand ...

In hemophilia, an increasing number of patients ... preferably through block trades and in the open market. Shares acquired will be canceled and will have an accretive effect to Sanofi's earning ...

Hemophilia: Hemophilia is a genetic disorder ... Paroxysmal Nocturnal Hemoglobinuria (PNH): PNH is a rare acquired blood disorder characterized by the destruction of red blood cells, white blood ...

The company also develops treatments for obesity, growth disorders, and hemophilia ... where smaller brands are acquired and scaled. This strategy is expected to continue, with a focus on ...

Our products that we acquired, we expect that will deliver ... There are also two new hemophilia drugs (one approved as Hympavzi, the other in clinical studies), alopecia and growth hormone ...

Pfizer’s PFE non-COVID operational revenues improved in the first three quarters of 2024, driven by its key in-line products like Vyndaqel and Eliquis, new launches like Abrysvo and newly acquired ...